Dr. Michael Postow on the Toxicities of Melanoma-Treating Targeted Therapy Combinations

http://youtu.be/s9qbr2K56Zg Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/